All In Biotech

Drug Trial Radar · NCT01455896

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Jan 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,156

Actual

Start

Mar 2013

Primary completion

Mar 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Intarcia TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.

Conditions

  • Type 2 Diabetes

Interventions

  • ITCA 650Drug

    ITCA 650

  • ITCA placeboOther

    ITCA placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. time to first occurrence of any event included in the MACE cardiovascular composite endpoint (CV death, non fatal MI, non fatal stroke, or hospitalization for unstable angina),Time frame: 2 years

Locations

42 sites in 9 countries. Site status is shown where the registry gives one.

  • Study Site

    Chandler, Arizona

  • Intarcia Therapeutics, Inc

    Hayward, California

  • Study Site

    Long Beach, California

  • Study Site

    Port Hueneme, California

  • Study SIte

    San Diego, California

  • Study Site

    Bradenton, Florida

  • Study Site

    New Port Richey, Florida

  • Study Site

    Palm Harbor, Florida

  • Study Site

    Chicago, Illinois

  • Study Site

    Avon, Indiana

  • Study Site

    Evansville, Indiana

  • Study Site

    Franklin, Indiana

  • Study Site

    Greenfield, Indiana

  • Study Site

    Muncie, Indiana

  • Study Site

    Newton, Kansas

  • Study Site

    Wichita, Kansas

  • Study Site

    Wichita, Kansas

  • Study Site

    Metaire, Louisiana

  • Study Site

    Rochester, Michigan

  • Study Site

    St Louis, Missouri

  • Study Site

    Billings, Montana

  • Study Site

    Las Vegas, Nevada

  • Site not named

    Las Vegas, Nevada

  • Study Site

    Winston-Salem, North Carolina

  • Study Site

    Cincinnati, Ohio

  • Study Site

    Columbus, Ohio

  • Study Site

    Franklin, Ohio

  • Study Site

    Pittsburgh, Pennsylvania

  • Study Site

    Uniontown, Pennsylvania

  • Study Site

    Greer, South Carolina

  • Study Site

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Study Site

    Dallas, Texas

  • Study Site

    San Antonio, Texas

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Hvidovre, Denmark

  • Site not named

    Oulu, Finland

  • Site not named

    Bad Lauterberg im Harz, Lower Saxony, Germany

  • Site not named

    Sopot, Poland

  • Site not named

    Martin, Slovakia

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.